Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.
Status:
Terminated
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
In this Phase II study we investigate the benefit of cabozantinib treatment for patients with
locally advanced or metastasized urothelial cell carcinoma who have been pre-treated with
checkpoint inhibitors only (cohort 1) or who have been pre-treated with cisplatin-based
chemotherapy and checkpoint inhibitors (cohort 2). We are lacking adequate response and
outcome data in patients after immunotherapy and consider that this study will improve future
treatment modalities for this important patient cohort.
Phase:
Phase 2
Details
Lead Sponsor:
Johannes Gutenberg University Mainz
Collaborator:
Interdisciplinary Center Clinical Trials (IZKS), University Medical Center Mainz